{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:50:51Z","timestamp":1787986251140,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jad.2025.121041","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:07:56Z","timestamp":1766534876000},"page":"121041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neurological drugs induced congenital anomalies: A pharmacovigilance analysis of neonatal reports in the FDA adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"398","author":[{"given":"Haiyan","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chufeng","family":"Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.121041_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.schres.2019.11.019","article-title":"Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011","volume":"215","author":"Anderson","year":"2020","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5603\/GP.a2017.0007","article-title":"Effect of antidepressants use in pregnancy on foetus development and adverse effects in newborns","volume":"88","author":"Ba\u0142kowiec-Iskra","year":"2017","journal-title":"Ginekol. Pol."},{"issue":"8","key":"10.1016\/j.jad.2025.121041_bb0015","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"8","author":"Bromley","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.jad.2025.121041_bb0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ajog.2007.08.044","article-title":"Antifungal drugs and the risk of selected birth defects","volume":"198","author":"Carter","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50366","article-title":"Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations","volume":"6","author":"Choi","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.jad.2025.121041_bb0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2217\/pgs-2017-0036","article-title":"Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study","volume":"18","author":"Daud","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"23","key":"10.1016\/j.jad.2025.121041_bb0035","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.2021.20191","article-title":"Assessment of the safety of common medications used during pregnancy","volume":"326","author":"Dude","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jad.2025.121041_bb0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1474-4422(12)70306-X","article-title":"Diagnosis of acute neurological emergencies in pregnant and post-partum women","volume":"12","author":"Edlow","year":"2013","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00228-019-02769-z","article-title":"Second-generation antipsychotics and pregnancy complications","volume":"76","author":"Ellfolk","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.121041_bb0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/bdra.23491","article-title":"Systematic procedure for the classification of proven and potential teratogens for use in research","volume":"106","author":"Eltonsy","year":"2016","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"issue":"12","key":"10.1016\/j.jad.2025.121041_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123127","article-title":"Prescriptions of antipsychotics in younger and older geriatric patients with polypharmacy, their safety, and the impact of a pharmaceutical-medical dialogue on antipsychotic use","volume":"10","author":"Gebauer","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.jad.2025.121041_bb0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/humupd\/dmp052","article-title":"Teratogenic mechanisms of medical drugs","volume":"16","author":"van Gelder","year":"2010","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.jad.2025.121041_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.645555","article-title":"Genetic susceptibility to drug teratogenicity: a systematic literature review","volume":"12","author":"Gomes","year":"2021","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.jad.2025.121041_bb0070","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.4088\/JCP.12r07966","article-title":"Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0075","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bpobgyn.2013.07.007","article-title":"Neurological disorders","volume":"27","author":"Haider","year":"2013","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061328","article-title":"Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study","volume":"12","author":"Heinonen","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jad.2025.121041_bb0085","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213786","article-title":"Use of antiseizure medications early in pregnancy and the risk of major malformations in the newborn","volume":"105","author":"Hernandez-Diaz","year":"2025","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jad.2025.121041_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40263-012-0006-1","article-title":"Sudden unexpected death in epilepsy. Potential role of antiepileptic drugs","volume":"27","author":"Hesdorffer","year":"2013","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.jad.2025.121041_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294996","article-title":"Maternal exposure to SSRIs or SNRIs and the risk of congenital abnormalities in offspring: a systematic review and meta-analysis","volume":"18","author":"Huang","year":"2023","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jad.2025.121041_bb0100","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.121041_bb0105","article-title":"Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study","volume":"368","author":"Huybrechts","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jad.2025.121041_bb0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamapsychiatry.2022.4109","article-title":"Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US","volume":"80","author":"Huybrechts","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4997\/JRCPE.2013.112","article-title":"Neurological diseases in pregnancy","volume":"43","author":"Kevat","year":"2013","journal-title":"J. R. Coll. Physicians Edinb."},{"issue":"3","key":"10.1016\/j.jad.2025.121041_bb0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-2008-1079337","article-title":"Teratogenicity of antiepileptic medications","volume":"28","author":"Kluger","year":"2008","journal-title":"Semin. Neurol."},{"issue":"8","key":"10.1016\/j.jad.2025.121041_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290614","article-title":"A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies","volume":"18","author":"Kulkarni","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bcpt.12497","article-title":"First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review","volume":"118","author":"Lassen","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0135","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/beog.2001.0234","article-title":"Drugs in pregnancy. Anticonvulsants and drugs for neurological disease","volume":"15","author":"Lowe","year":"2001","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/FJC.0b013e31821c471b","article-title":"Drug exposure in pregnancy and heart defects","volume":"58","author":"Matok","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"10","key":"10.1016\/j.jad.2025.121041_bb0145","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.euroneuro.2015.07.010","article-title":"Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase","volume":"25","author":"Montastruc","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.121041_bb0150","article-title":"Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study","volume":"356","author":"Nembhard","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/acps.13431","article-title":"Mirtazapine exposure in pregnancy and fetal safety: a nationwide cohort study","volume":"145","author":"Ostenfeld","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.jad.2025.121041_bb0160","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00213-013-3060-6","article-title":"Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study","volume":"228","author":"Peng","year":"2013","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.jad.2025.121041_bb0165","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(05)70224-6","article-title":"Birth defects after prenatal exposure to antiepileptic drugs","volume":"4","author":"Perucca","year":"2005","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0170","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.4088\/JCP.14m09241","article-title":"Selective serotonin reuptake inhibitors and congenital heart anomalies: comparative cohort studies of women treated before and during pregnancy and their children","volume":"77","author":"Petersen","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.121041_bb0175","article-title":"Prevalence of neurodevelopmental disorders in families of women taking psychotropic medication during pregnancy","author":"Reddy","year":"2025","journal-title":"Paediatr. Perinat. Epidemiol."},{"issue":"4","key":"10.1016\/j.jad.2025.121041_bb0180","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.reprotox.2011.09.004","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations","volume":"32","author":"Sadler","year":"2011","journal-title":"Reprod. Toxicol."},{"issue":"2","key":"10.1016\/j.jad.2025.121041_bb0185","article-title":"Differences in antipsychotic-related adverse events in adult, pediatric, and geriatric populations","volume":"9","author":"Sagreiya","year":"2017","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.jad.2025.121041_bb0190","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamainternmed.2022.0375","article-title":"Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study","volume":"182","author":"Straub","year":"2022","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0195","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/15357597231191953","article-title":"What you Don\u2019t know can hurt you: psychiatric effects of prenatal anti-seizure medications","volume":"23","author":"Terman","year":"2023","journal-title":"Epilepsy Curr."},{"issue":"4","key":"10.1016\/j.jad.2025.121041_bb0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1059-1311(98)80020-4","article-title":"Sudden unexpected death in epilepsy: is carbamazepine implicated?","volume":"7","author":"Timmings","year":"1998","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.jad.2025.121041_bb0205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1474-4422(12)70103-5","article-title":"Teratogenic effects of antiepileptic drugs","volume":"11","author":"Tomson","year":"2012","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0210","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/epd.2019.1105","article-title":"Management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy","volume":"21","author":"Tomson","year":"2019","journal-title":"Epileptic Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.121041_bb0220","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.4088\/JCP.15r10483","article-title":"A systematized review of atypical antipsychotics in pregnant women: balancing between risks of untreated illness and risks of drug-related adverse effects","volume":"78","author":"Tosato","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0225","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/cap.2019.0123","article-title":"Frequency and correlates of acute dystonic reactions after antipsychotic initiation in 441 children and adolescents","volume":"30","author":"Tural","year":"2020","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.jad.2025.121041_bb0230","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/14740338.2015.1084288","article-title":"Foetal safety of old and new antiepileptic drugs","volume":"14","author":"Verrotti","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.jad.2025.121041_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-024-01131-x","article-title":"Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: a systematic review and network Meta-analysis of congenital malformations and prenatal outcomes","volume":"39","author":"Wang","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2025.121041_bb0240","article-title":"Mirtazapine versus other antidepressive agents for depression","volume":"12","author":"Watanabe","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.jad.2025.121041_bb0245","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting system (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725024838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725024838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:22:06Z","timestamp":1781702526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725024838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S0165032725024838"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.121041","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological drugs induced congenital anomalies: A pharmacovigilance analysis of neonatal reports in the FDA adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.121041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121041"}}